Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mesoblast Ltd's Cell Therapy Strengthens Native Heart Function In Patients With End-stage Heart Failure On Assisted Circulatory Support

Monday, 18 Nov 2013 05:22pm EST 

Mesoblast Ltd announced that patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left ventricular assist device (LVAD) heart pump to maintain circulation may obtain specific benefit to their native heart from a single dose of Mesoblast’s mesenchymal precursor cells (MPCs) injected directly into their heart during surgery, a multicenter team of researchers within the United States National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, New York, have found. The results of the Phase 2 trial assessing the safety and efficacy of injecting a single dose of MPCs directly into the heart muscle of end-stage heart failure patients receiving an LVAD for either bridge-to-transplant or as a destination therapy were presented on November 18, 2013, at the American Heart Association Scientific Sessions 2013 being held in Dallas, Texas. The double-blind, placebo-controlled multicenter trial was performed across 11 sites in the United States, and randomized 30 end-stage heart failure patients 2:1 to receive either a single 25 million dose injection of MPCs or control media into the native heart at the time of LVAD implantation. LVAD weaning, defined as a transient reduction in pump speed for at least 20 minutes, was attempted in all patients at predetermined intervals to assess native myocardial function. 

Company Quote

-0.12 -2.84%
28 Nov 2014